KENDON PMAS FUNGICIDE

Main information

  • Trade name:
  • KENDON PMAS FUNGICIDE
  • Class:
  • AgChem
  • Medicine domain:
  • Plants
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • KENDON PMAS FUNGICIDE
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • GLADIOLUS | SEED POTATO | TURF AND LAWN | EVENING-FLOWER | GLADIOLI | REDFLOWER | WALL
  • Therapeutic area:
  • FUNGICIDE
  • Therapeutic indications:
  • BACTERIAL GLADIOLUS SCAB | BLACK STEM CANKER SCURF | BOTRYTIS LEAF SPOT OR CORM COLLAR ROT | BROWN PATCH | COMMON POTATO SCAB | COPPER SPOT | CORM GLADIOLUS ROT - P. GLADIOLI | CORM GLADIOLUS ROT - SEPTORIA GLADIOLI | DOLLAR SPOT | FOOT ROT | PINK REDTHREAD PATCH | POWDERY SCAB | SPRING DEAD SPOT | BLACK SCURF | CANKER | DAMPING OFF | DRECHSLERA SPP. | FUSARIUM SPP. | HELMINTHOSPORIUM SPP. | HYPOCOTYL ROT | RHIZOCTONIA SPP. | ROOT ROT | SEPTORIA BLIGHT | SOIL FUNGI | STREPTOMYCES SCABIES | WIRE STEM

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Cancelled
  • Authorization number:
  • 30665
  • Last update:
  • 09-08-2016

There are no safety alerts related to this product.

20-12-2018


Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-c

Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-c

Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt, Treatment of beta-thalassaemia intermedia and major, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

28-8-2018

EU/3/18/2058 (IQVIA RDS Ireland Limited)

EU/3/18/2058 (IQVIA RDS Ireland Limited)

EU/3/18/2058 (Active substance: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate) - Orphan designation - Commission Decision (2018)5730 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/099/18

Europe -DG Health and Food Safety

17-4-2018

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Active substance: Ornithine phenylacetate) - Transfer of orphan designation - Commission Decision (2018)2355 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/105/11/T/03

Europe -DG Health and Food Safety